SCHEMBL6479848

SCHEMBL6479848

Nc1nc2ccccc2n1-c1ncnc(Nc2cccc(CC(=O)NCc3ccccn3)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.54
MTOR P42345 6/20 0.54
POLB P06746 1/20 0.46
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
BACE1 P56817 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ADORA3 P0DMS8 2/20 0.40
ADORA2A P29274 2/20 0.40
ADORA2B P29275 2/20 0.40
ADORA1 P30542 2/20 0.40
KDR P35968 2/20 0.40
PIK3CD O00329 1/20 0.40
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
TGFBR2 P37173 1/20 0.40
PIK3CB P42338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479199 0.84 PIK3CA (0.52) PIK3CAMTORKDRPIK3CDRAF1
SCHEMBL14214732 0.77 SCN9A (0.59) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL6485821 0.75 PIK3CA (0.52) PIK3CAMTORKDRPIK3CDRAF1
SCHEMBL6479012 0.74 PIK3CA (0.47) PIK3CAMTORKDRPIK3CDRAF1
SCHEMBL14380903 0.73 AURKA (0.52) PIK3CAMTORKDRLCK
SCHEMBL6492733 0.71 PIK3CA (0.50) PIK3CAMTORKDRPIK3CDRAF1
SCHEMBL14214728 0.71 MKNK1 (0.53) PIK3CAMTORKDRPIK3CDPIK3CB
SCHEMBL3244139 0.70 PIK3CA (0.55) PIK3CAMTORPOLBKMT2ANPSR1
SCHEMBL14214617 0.68 KDR (0.53) PIK3CAMTORKMT2AMEN1ADORA3
SCHEMBL14214627 0.67 AURKA (0.48) PIK3CAMTORSMN1; SMN2KDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA PIK3CA 475/4885MTOR 1843/4885POLB 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.